In late 2020, the US Food and Drug Administration (FDA) approved a lipid-based mRNA
vaccine for the prevention of COVID-19, which has pushed this field to be more closely …

Cancer immunotherapy and vaccine development have significantly improved the fight
against cancers. Despite these advancements, challenges remain, particularly in the clinical …

Chimeric antigen receptor (CAR) T cell therapy has demonstrated remarkable efficacy in
haematological malignancies. However, although viral vector-based methods are effective …

Natural Killer (NK) cells are exciting candidates for cancer immunotherapy with potent innate
cytotoxicity and distinct advantages over T cells for Chimeric Antigen Receptor (CAR) …

mRNA applications have undergone unprecedented applications—from vaccination to cell
therapy. Natural killer (NK) cells are recognized to have a significant potential in …

Autoimmune disorders have risen to be among the most prevalent chronic diseases across
the globe, affecting approximately 5–7% of the population. As autoimmune diseases steadily …

Chimeric antigen receptor (CAR)-T cells have made significant advancements in the field of
adoptive immune cell therapies and the treatment of hematological malignancies. However …

In recent years, lipid nanoparticles (LNPs) have attracted extensive attention in tumor
immunotherapy. Targeting immune cells in cancer therapy has become a strategy of great …

Messenger RNA (mRNA) therapy has been applied to the treatment of various human
diseases including malignant tumors. Increasing evidences have shown that mRNA can …

Conventional cancer therapy has major limitations, including non-specificity, unavoidable
side effects, low specific tumor accumulation and systemic toxicity. In recent years, more …